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Fragile X Syndrome (FXS) is the most common form of inherited intellectual and developmental 
disability, and a known genetic cause of autism. Individuals with FXS present with deficits in 
cognition, social skills, behavior, language and sensory processing skills; all of which are 
commonly assessed through standardized and norm-referenced assessments. However, these 
outcome measures are sometimes not sensitive to contextually based changes in daily life. 
Further, there is limited research employing qualitative methods in the FXS literature. The 
purpose of this research was to examine family perspectives collected via semi-structured 
interviews as part of a randomized controlled medication trial of sertraline (Zoloft) on children 
two to six years old diagnosed with FXS. The constant comparison method was used to analyze 
differences in family expressions of their child’s improvements over the course of the 6-month 
clinical trial. Twelve interviews were analyzed, six-treatment, six-placebo, and all coding was 
done blind to group assignment. Results indicated greater improvements in the treatment group 
when compared to the placebo group in: anxiety, receptive / expressive communication, 
maladaptive behaviors and some sensory issues. These preliminary findings warrant a need for 










         Fragile X Syndrome (FXS) is the most common form of inherited intellectual and 
developmental disability (IDD) and is also the most common genetic form of autism spectrum 
disorder (ASD) (Hagerman et al., 2010; National Fragile X Foundation [NFXF], 2015). Shared 
characteristics of ASD and FXS include limited social interaction, language deficits and 
communication impairments, sensory processing differences, anxiety, and maladaptive behaviors 
(Case-Smith & Arbesman, 2008). Living with FXS not only affects the individuals diagnosed 
with FXS, but also their families. Raising a child with FXS can significantly impact the families’ 
health and quality of life, their ability to navigate health and educational systems, ability to 
overcome social stigma, define the family identity, and establish family occupational roles 
(Tomlin & Swinth, 2015). While families are learning about FXS through their own disability 
experience, there is little representation of family voice and context via qualitative methods in 
the research literature. While standardized and norm-referenced assessments and parent checklist 
are widely used as outcome measures and provide quantitative data, their application in a clinical 
trial of sertraline with young children with FXS may not be appropriate to measure contextual 
changes. These outcome measures are limited in context and not reflective of functional changes 
for the IDD population. To date, research literature focuses primarily on quantitative methods 
and the medical model. Furthermore, the use of standardized and norm-referenced outcome 
measures leaves populations with IDD vulnerable to flooring effects. By including families’ 
experiences of FXS, future treatments can be geared toward improving the child with FXS’s 
participation in desired occupations. 
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     The purpose of this research is to examine family perspectives collected during baseline 
and follow-up interviews as part of a randomized, double-blinded, six-month, controlled 
medication trial of sertraline (Zoloft) on children two to six years old diagnosed with FXS. Semi-
structured interviews were used to understand family expressions and contexts of their child’s 
improvements over the course of the clinical trial. This qualitative data may prove to be a more 
sensitive measure in contrast to standardized measurements, which show limited, change over 
time with IDD populations. 
Literature Review 
         The following literature review examined research conducted in various areas involving 
FXS. Topics included detailed information about FXS, treatments for FXS including behavioral 
and pharmacological interventions, how FXS affects families, and outcome measures used to 
help better understand FXS. Additionally, the literature review discussed the completed, 
randomized controlled trial research study in which the interviews were conducted. This 
proposal highlighted the importance for further research to be done on FXS and family 
perspectives. 
FMRP and Physiology 
FXS is caused by an expanded CGG repeat which leads to cellular dysregulation of the 
Fragile X Mental Retardation Protein (FMRP) (Hagerman, Hoem, & Hagerman, 2010). The lack 
of the FMRP in FXS causes dysregulation and often the overexpression of its target genes. 
Mutations in the FMR1 gene lead to transcriptional silencing and loss of FMRP expression 
resulting in FXS. Farzin et al. (2006) explained that FMRP is important for the development and 
maturation of dendritic spines and synaptic connections. In other words, the lack of FMRP is 
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responsible for the cognitive, physical, and behavioral impairments seen in patients with FXS, 
making it the most common heritable form of mental retardation. 
Heritability and Prevalence 
In the general population, approximately one in 3600 males and one in 6000 females 
have FXS (Farzin et al., 2006). FXS has a premutation and a full mutation. In premutation, the 
CGG-repeat ranges from 55 to 200 repeats in a specific region of the FMR1 gene. In the full 
mutation, this same region of the FMR1 gene spans the length of greater than 200 repeats 
(Hagerman et al., 2010). The more CGG repeats found in the genetic code, the less FMRP is 
expressed which causes relatively more cognitive, physical, and behavioral deficits. When a 
premutation female carrier has a child there is an increased chance that CGG-repeat will expand 
into a full mutation. Most individuals with a premutation are neither developmentally disabled 
nor do they have autism. However, a subgroup of individuals with the FXS premutation do 
experience cognitive, emotional and/or behavioral involvement, but with less severity than those 
possessing full mutation of FXS. 
Wang et al. (2010) assert there is strong association between FXS and autism when 
examining the molecular and symptomatic overlap between the two disorders. Nearly 40% of 
individuals with FXS also have ASD and 10% of individuals with ASD also present with FXS 
(National Fragile X Foundation, 2015). The overlap in neurotransmission and symptomatology 
affords popular treatments for the broader spectrum of autism to possibly be used in treating 
those with FXS (Hagerman, Lauterborn, Au, & Berry-Kravis, 2012).   
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FXS with and without Autism 
 FXS can occur with or without autism. In particular, FXS is the most common single 
gene cause of autism, responsible for 2% to 6% of all cases of autism. For individuals diagnosed 
with FXS, Wang, Berry-Kravis, and Hagerman (2010) reported the prevalence of ASD to be 
approximately 18%–36%. The National Fragile X Foundation (NFXF) with the Center for 
Disease Control report that as of 2016, the prevalence of FXS with ASD is 46%, demonstrating 
an increase in this comorbidity (NFXF, 2016) when compared to the prevalence in Wang, Berry-
Kravis, and Hagerman’s research (2010).  In comorbid ASD and FXS, Wang et al. (2010) 
emphasized that such individuals present higher degrees of severity of symptoms and deficits in 
overall functioning when compared to children diagnosed with FXS alone. 
Males vs. Females with FXS 
Males and females inherit the premutation and full mutation of the FMR1 gene 
differently (Hagerman et al., 2010). A female with a premutation could have inherited a FXS 
premutation from either parent. In male, the premutation derives from the biological female 
carrier. However, all children having full mutation, regardless of gender, have a biological 
carrier mother. Also, the propensity for transmission of a full mutation allele increases with an 
increasing CGG repeat number in the mother. Decreased levels of FMRP correlate with 
increased clinical implications including physical, cognitive and structural/functional brain 
involvement. Children with FXS who do not meet the criteria for an ASD diagnosis still 
nonetheless often exhibit one or more autistic features such as hand flapping, poor eye contact 
and tactile defensiveness. 
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One study by Farzin et al. (2006) noted some key differences between males and females 
with FXS. For both genders, premutation carriers are at higher risk for developmental problems, 
particularly those who present clinically with behavioral difficulties. FXS is less likely to occur 
in females and its presentation is usually less severe. Also, most female carriers of FXS are less 
likely to experience developmental or behavioral problems in childhood. In contrast, males with 
full mutation FXS show greater instances of maladaptive behaviors and developmental deficits 
(Wang et al., 2010). Males have a higher rate of comorbid FXS and ASD. The NFXF reports in 
2016 that 46% comorbidity occurs in males versus 16% in females (NFXF, 2016). In an older 
2010 study, the percentage of both FXS and ASD was 5% in females while it occurred as 10-
15% of the time in male carriers (Wang et al., 2010), showing a dramatic increase of heritability 
in both males and females in the last few years. 
For those with both FXS and autism, there is a spectrum of involvement both cognitively 
and behaviorally, with intelligence quotient (IQ) values ranging from severely intellectually 
impaired to typical, particularly in females. However, there is a strong association between low 
IQ and the autism diagnosis in both males and females with FXS (Hagerman et al., 2010).  
Phenotype of FXS 
     Behavioral. Behavioral issues are a key feature of the FXS phenotype, encompassing 
attention difficulties, hyperactivity/impulsivity, social anxiety, repetitive/perseverative behaviors, 
poor eye contact, self-injurious behavior (SIB), aggression, irritability, and sleep problems 
(Kronk et al., 2010; Kurtz, Chin, Robinson, O’Connor, & Hagopian, 2015; Wang et al., 2012). 
Anxiety-related symptoms common in individuals with FXS include shyness, social phobia, 
obsessive compulsive disorder (OCD)-like symptoms, hyperarousal, and attention-deficit 
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hyperactivity disorder (ADHD)-like symptoms (Berry-Kravis et al., 2013). Common forms of 
SIB in individuals with FXS include finger/hand biting, head/self-hitting, picking/pulling 
skin/hair, and self-scratching (Kurtz, 2015). Recent prevalence estimates for SIB in males with 
FXS range from 39% to 79% (Kurtz, 2015). Parents of children with FXS report that SIB and 
aggression are among the most stressful and life impacting behavioral challenges as they often 
result in injury to self or others (Berry-Kravis et al., 2015). 
 Physical. The typical physical features of FXS in both males and females are long, 
narrow face, prominent ears, highly arched palate, hypotonia, hypermobility in the 
metacarpophalangeal joints, scoliosis, and flat feet (NFXF, 2016). Macro-orchidism, abnormally 
large testes in males and enlarged ovaries in females, are a common phenotype observed in 
individuals with FXS but is rare before puberty and becomes more evident as the child grows 
(NFXF, 2016). Ocular problems present in children with FXS include strabismus, or “lazy eye”, 
and ptosis, or drooping eyelids, both of which are thought to be caused by low muscle tone. 
Additionally children with FXS may have nystagmus, shaking of the iris in a back and forth 
motion, which may in turn cause near- or far-sightedness (NFXF, 2016). Cardiac abnormalities 
which include “functional” or “innocent” murmur can lead to mitral valve prolapse in individuals 
with FXS (NFXF, 2016).  
     Cognitive.  Individuals with FXS exhibit a range of cognitive problems such as 
intellectual disability and deficits in social cognition and executive functioning (Berry-Kravis et 
al., 2015). Intellectual disabilities are characterized by significant limitations in both intellectual 
functioning and in adaptive behavior including social cognition. Intellectual functioning and 
adaptive behavior are needed for many everyday social and practical skills and interactions. FXS 
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is the most common inherited cause of intellectual delays with an average IQ of 40 (Klusek et 
al., 2015; Merenstein et al., 1996). Males with FXS display mild to moderate intellectual delays 
and demonstrate adaptive skills in the low-average range (Klusek et al., 2015). Approximately 
50% of women with full mutation FXS have IQs in the borderline or mild intellectual disability 
range (Hagerman, Jackson, & Amiri, 1992). 
Social cognition refers to the processing of information about the social world, e.g., the 
ability to recognize differences in people’s knowledge or perspectives (Farzin, Rivera, & Hessl, 
2009). Impairments in some aspects of social cognition exceed the impairments seen in other 
domains, especially in individuals with comorbid FXS and ASD (Farzin et al., 2009). Executive 
function involves the management of cognitive processes such as working and explicit memory, 
sequential processing, reasoning, task flexibility, problem-solving, planning, and execution. 
There is compelling evidence that executive function deficits are highly characteristic of 
individuals with FXS (Berry-Kravis et al., 2013).  
    Language. Language impairments common in individuals with FXS are seen in the 
following areas: prelinguistic, receptive, expressive, and speech intelligibility (Berry-Kravis et 
al., 2013; Finestack, Richmond, & Abbeduto, 2010). Children with FXS that present with 
language impairments also show high rates of verbal perseveration and bursts of rapid, poorly 
articulated speech (Berry-Kravis et al., 2015). Expressive language deficits common in 
individuals with FXS often inhibit the types of social interactions that foster language growth 
and development in typically developing children. Lower IQ and more severe ASD symptoms 
are associated with more serious language problems (Berry-Kravis et al., 2013).  
OCCUPATIONS AS OUTCOME MEASURE IN A CLINICAL TRIAL 13 
 
 
Sensory. Sensory processing deficits common in children with FXS also influence 
occupational performance, including self-care, school functioning, and play. Deficits in sensory 
processing manifests as unusual responses to typically neutral input such as noise, tactile, visual 
and olfactory stimuli (Hagerman, 1996). Clinical observations of behavioral symptoms of FXS 
such as social phobia, anxiety, hyperarousal and hyperactivity have been thought to reflect 
difficulties in sensory processing, the process in which the nervous system receives input from 
the senses and translates them into appropriate motor and behavioral responses (Baranek, Chin, 
Hess, Yankee, Hatton, & Hooper, 2002). Sensory processing is critical for understanding the 
environment and sense of self, including sight, hearing, taste, touch, smell, body awareness and 
balance (Baranek et al., 2002). Miller et al. (1999) found that children with FXS manifested the 
most severe sensory processing disorders of all the clinical groups in their studies including ASD 
and ADHD.  
The Importance of Family Perspective on FXS 
Brett (2002, p. 827) emphasized that “parents often hold the key in accessing their child’s 
experiences and providing essential insight into their child’s world.” The lives of children with 
FXS and parents closely influence one another. Therefore, parents’ concerns are informative and 
essential to developing an alternative model for examining the challenges of raising children 
with disabilities, including children with FXS. Detailed parent perspectives can illuminate a 
child’s behavior in the home and social issues that they may face.  Brett (2002) explains that 
society must dismantle the stigma of disability and promote a socially aware, active and 
inclusive culture. 
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Research suggested that problem behaviors of children with FXS have the greatest impact 
on parents and families as compared to those with cognitive impairment (Bailey Jr. et al., 2000). 
Because biological mothers of children with FXS are carriers of the premutation of FXS, these 
women are more genetically susceptible to depression, social anxiety, and possibly unstable 
affection toward the child (Abbeduto et al., 2004; Bailey et al., 2008). Fathers of children with 
FXS are also affected by child-related stress, although mothers are usually considered as playing 
a more important role in parenting (Hartley, Seltzer, Head, & Abbeduto, 2015). Although 
research has shown the predisposed risk in parents’ mental health in families with FXS, other 
research suggested differing findings by examining family perspectives. One study examined the 
perceived quality of life in mothers of children with FXS through self-report. The findings 
indicated that mothers of children with FXS did not have a perceived lower quality of life than 
average women. Researchers proposed although it was reported that parents faced challenges and 
stressors in an unsupportive social environment, mothers of children with FXS held hope in the 
disability, which might result in positive perspective of quality of life (Wheeler, Skinner, & 
Bailey, 2008). Furthermore, Hauser, Kover, and Abbeduto (2014) conducted a short-term 
longitudinal study to examine the bidirectional relationships between maternal mental health 
status, maternal stress, family environment, and behavioral functioning of children with FXS. 
The study suggested that maternal mental health status had no significant relationship with 
changes in levels of the child’s challenging behavior. Contrary to popular belief, high rates of the 
child’s challenging behavior was found to be associated with improvements in maternal 
depression over time. In turn, heightened levels of challenging behaviors increased maternal 
closeness toward the child over time (Hauser, Kover, & Abbeduto, 2014). Researchers explained 
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that heightened challenging behaviors gather additional external support, either from the father, 
other family members, or even professionals. These additional supports relieve emotional 
burdens of the mothers; therefore potentially decrease symptoms of mental illness. Moreover, the 
positive relationship of closeness and challenging behavior can be explained by the increased 
time spent and sense of protection from the mothers with their children (Hauser, Kover, & 
Abbeduto, 2014). These unanticipated results represent a need to further examine family 
perspectives in order to provide a contextual base to the study.  
Treatment of FXS  
Behavioral intervention. A variety of professionals participate in behavioral interventions 
for children with FXS.  Practitioners often include special education teachers, occupational 
therapists, speech and language therapists, physical therapists, and behavioral therapists. An 
interdisciplinary approach may be adopted in the intervention process and is typically outlined in 
an Individualized Educational Plan (IEP) in a school-based setting.  
Despite extensive research on the behavioral phenotype of FXS, relatively few studies have 
been conducted on the effectiveness of behavioral treatments for children with FXS (Hagerman, 
2009). Researchers believe the lack of research in this domain is due to overemphasis of 
biological factors of FXS (Moskowitz, Carr, & Brook, 2011). Parents of children with FXS 
assume that their children’s problem behavior is permanently determined by the underlying 
FMRP deficiency. This leads to the belief that medical treatment is a more superior approach 
than behavioral treatment (Hall, 2009). Behavioral interventions for FXS are generally 
individualized and they normally utilize their own clinical experience in association with their 
knowledge in typical behavioral phenotype of FXS to guide their treatment approaches 
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(Hagerman, 2009). Contemporary strategies that treat ASD and other developmental disabilities 
have shown positive outcomes on the behaviors of children with FXS who present behaviors 
similar to children with ASD such as hyperarousal, impulsivity, and SIB (Hagerman, 2009).  
Intervention methods that aim to improve behaviors of children with FXS include applied 
behavior analysis (ABA) and environmental modifications. Behavioral-specific models, such as 
ABA, are used in ASD and FXS treatments. This includes the functional behavioral analysis and 
the antecedent-behavior-consequence models. These are utilized to address and replace 
maladaptive behaviors through positive reinforcement of adaptive behaviors (Hills-Epstein, 
Riley, & Sobesky, 2002). Studies also show that modified home environments are associated 
with better adaptive behavior and fewer autistic behaviors for children with FXS (Glaser et al., 
2003; Hessl et al., 2001). These studies suggest that modifications in home and classroom 
environments tailored for children with FXS may lead to better behavioral outcomes.  
Treatments comparable in treating ASD are applicable to children with FXS as well. 
Available models include: the Treatment and Education of Autistic and Related Communication- 
Handicapped Children (TEACCH) model, the Denver model, and Pivotal Response Training 
(PRT). Although these are well-established models for ASD, Hagerman (2012) states that these 
treatment models have also been helpful for many children with FXS. Social issues for children 
can be addressed by behavior modification interventions aimed at improving social eye contact. 
As social problems can also be caused by heightened responses to sensory stimuli, addressing the 
sensory input by reducing environmental stimuli and improving sensory coping skills has the 
potential to generate improvements in behavior. (Hagerman, 2009).  
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Although behavioral intervention strategies for FXS typically are based on ASD treatment, 
the potential of developing effective behavioral intervention specified for FXS has been 
supported by a number of studies. For instance, Moskowitz et al. (2011) collaborated with three 
families with children with FXS and developed a set of individualized behavioral treatments 
strategies. Some examples of interventions included manipulating setting events, increasing 
predictability, providing choices, social stories, etc. Of the three children who participated in the 
study, all three showed substantial behavioral improvements in the most problematic behaviors 
identified by the mothers. This research indicates that although FXS is known as a genetic 
condition that is presumably unalterable, the potential of improving problem behaviors should 
not be overlooked. Additionally, Kurtz, Chin, Robinson, O’Connor, and Hagopian (2015) 
conducted a consecutive case-series analysis that reports on functional analysis and treatment of 
problem behavior of nine children with FXS. All analyses were done using multi-element 
designs that included attention, demand, and play conditions. The findings suggest that 
functional-based behavioral interventions that are effective for individuals with IDD are also 
effective for children with FXS.  
Evidence supports combination treatment models that include behavioral intervention and 
pharmacological treatments (Reiss & Hall, 2007). Therefore, in addition to occupation-based 
behavioral therapy, some parents choose to have their child with FXS take medications, 
including selective-serotonin uptake inhibitor, or SSRIs.  
         Medical intervention - Selective-serotonin uptake inhibitors (SSRIs). SSRIs work by 
blocking the reabsorption of serotonin, thus leaving more serotonin available to improve mood 
(Brown & Stoffel, 2011). It is hypothesized that children with FXS have serotonin dysregulation 
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similar to children with ASD (Chugani, 1999; Hanson, 2014). The findings in the Hanson (2014) 
study suggest that use of SSRIs may be helpful in serotonin regulation for children with FXS. In 
particular, sertraline (trade name Zoloft), is “considered one of the most potent inhibitors of 
serotonin reuptake. Additionally, sertraline significantly prevents dopamine reuptake” (Hanson, 
2014, p. 113). Because sertraline is one of the most potent among SSRIs, it is possible that it is 
also the most effective SSRI treatment for children with FXS. 
         Current use in FXS. SSRIs are currently being prescribed to treat some children with 
FXS. According to Hagerman et al. (2009), SSRIs given at typical doses were helpful more than 
half the time in treating anxiety and other problems related to anxiety in children with FXS. 
SSRIs were shown to be helpful on the basis of survey reports and clinical trials (Hagerman et 
al., 2009). SSRIs can be helpful in changing behaviors and language development seen in 
children with FXS. Winarni et al. (2012) used retrospective chart review of 45 children with FXS 
between the ages of 12-50 months to measure the effects of sertraline. The children in the study 
experienced anxiety, irritability, and problems with social interaction. The 11 children who 
received sertraline had their medical charts compared with the 34 children who did not receive 
sertraline. The children who had received sertraline were found to have decreases in anxiety, 
irritability, and problems with social interaction. All children in the study were found to have 
improvements in language development; however, the children in the sertraline group displayed 
significant improvements in language development over the non-sertraline group. Finally, 
according to Hess et al. (2016), SSRIs are helpful in treating the phenotypical manifestations of 
FXS including communication and intellectual deficits, anxiety, and sensory processing 
challenges. While SSRIs are helpful in treating these deficits seen in FXS, no previous studies 
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have been done on children with FXS younger than five years old. Thus, the results from Hess et 
al.’s (2016) study show promise for sertraline use in children with FXS under the age of five, 
particularly in the areas of social participation and overall development. The findings in the 
aforementioned studies are significant as quantitative data supports the use of sertraline in 
children with FXS for language development, decreasing maladaptive behaviors, and social 
participation.  However, the outcome measures used in those studies lack a qualitative 
component sensitive enough to detect changes in daily life and overall functioning for IDD 
populations. 
Outcome Measures Commonly Used to Assess FXS and ASD 
To date, clinical trials on subjects with FXS have focused the evaluation of their outcomes 
with a battery of standardized assessments and structured parental surveys rather than qualitative 
data. Some frequently employed outcome measures include: Sensory Processing Measure (SPM) 
and Sensory Processing Measure-Preschool (SPM-P), Mullen Scales of Early Learning (MSEL), 
the Standardized Language Sampling Procedures (SLSP), The Aberrant Behaviors Checklist 
(ABC), and the Social Responsiveness Scale (SRS) (Berry-Kravis et al., 2013, Hessl et al., 
2016). Although these standardized assessments are widely used and offer sound psychometric 
and quantitative data, they lack sensitivity to clinically meaningful change, lack context and 
family voice, and may not be applicable for lower-functioning individuals (Berry-Kravis et al., 
2013). Moreover, Berry-Kravis et al. (2013) note that outcome measures that have been 
developed for symptom-based clinical trials in behaviorally defined disorders, such as autism 
and ADHD, might not be sufficiently sensitive or specific for disease-oriented interventions in 
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FXS. The gap between quantitative outcome measures and the daily lived experience of parents 
of children with FXS creates a need to incorporate interviews in the research procedure.   
Incorporating semi-structured caregiver interviews into the research procedure could 
provide context and voice for changes, are occupation-centered, explain the daily life impact of 
disability, and may identify potential outcomes for intervention in clinical trials. Hess et al.’s 
2016 “Family Meanings” study argues that inclusion of a sociocultural perspective within the 
context of a clinical trial affords consideration of a dynamic view of development - that is, 
simultaneous consideration of biological and sociocultural factors with the application of a 
bioecological framework. Therefore, the use of interviews is suggested to capture family voice 
and life with FXS in context. The use of parent interviews as a tool to measure outcomes in 
clinical studies may enhance practitioners’ and clinical researchers’ understanding of the 
complexities families may face. Parent interviews can also inform the scope and focus of 
outcome measures by identifying the most meaningful outcome variables to monitor and 
establish as behavioral and pharmacological treatment goals (Tomlin & Swinth, 2015).  
UC Davis MIND Institute Randomized Clinical Trial 
         A randomized controlled trial of sertraline was completed at the UC Davis, Medical 
Investigation of Neurodevelopmental Disorders (MIND) Institute (Hess et al., 2016). The results 
of Hess et al.’s 2016 study showed that no significant differences were observed in the MSEL 
expressive language subscales and CGI-I primary outcome measures for sertraline compared to 
placebo. Secondary measures revealed significant improvement in social participation on the 
SPM-P. Fine motor and visual perception were also significantly improved on the MSEL age 
equivalent scores for the sertraline treatment group when compared to the placebo group. Post 
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hoc analysis combining all MSEL age-equivalent scores (expressive, visual, receptive and fine 
motor) showed overall significant improvement. Results suggest sertraline had significant 
positive effect on social improvements and overall development. Adverse events (AEs) were 
similar between sertraline and placebo groups with no significant differences in characteristics of 
AEs observed between the groups. 
Families enrolled in the UC Davis MIND Institute sertraline clinical trial participated in 
semi-structured interviews at baseline and post testing. The baseline interviews posed questions 
focused on living with FXS and the impact on daily family life. Upon conclusion of the clinical 
trial, while the families were still blind to whether they were randomized to either the sertraline 
treatment or placebo groups, a second set of interviews were conducted asking families to reflect 
upon areas of possible improvement for their child who participated in the study (e.g. activity 
level, anxiety, sensory processing and communication) and whether there had been any 
subsequent impact on family life. 
After the six-month trial, children in the sertraline group were reported to have a 
significant increase in their social participation as compared to the placebo group. Social 
participation items on the SPM-P included: family outings, gatherings, activities with friends, 
and family errands (Hess et al., 2016). In addition to the SPM-P, conversational interviews at 
baseline and post intervention explored the complexities of daily life, experiences, and family 
meanings associated with various phenotypic manifestations of FXS (e.g. language / 
communication, behavior, sensory processing, and anxiety) (Hess, Ching & Hagerman, 2014). 
Via semi-structured interviews, families were asked to share their stories and experiences in their 
own words as a first-person account that focused on family hopes and meanings for participation 
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in this clinical trial rather than responding to a set of predetermined response choices. The 
interview results highlight the importance of how their child’s social participation greatly affects 
the understanding of family perspectives in the treatment of FXS. This research study aimed to 
find the potential for interviews to provide a deeper understanding of the lived experience of 
families.  
Conclusion 
         FXS is the most common form of inherited intellectual disability. Typical manifestations 
of FXS include sensory, language, behavioral, and social deficits. These deficits affect the family 
dynamics, and increase family stress and desire to seek effective interventions. However, 
medical management research for young children with FXS is emerging. Qualitative research 
examining family perspectives on the impact of medication on everyday functioning in young 
children with FXS is not currently part of the treatment literature. This research utilized semi-
structured interviews to empirically examine parental perspectives regarding medication 
effectiveness in everyday life contexts. While there has been a vast amount of quantitative 
research conducted on FXS, there is limited qualitative research. In addition, quantitative 
assessments lack sensitivity to clinically meaningful change and context. Rather, family 
perspectives, as a qualitative outcome measure have the potential to enrich analysis of clinical 
trials as an additional supplement to the current outcome measurement battery. The gaps in the 
research and the findings of previous sertraline studies support the need for further research 
surrounding FXS and family perspectives of raising a child with FXS.  
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Statement of Purpose 
Statement of Problem 
         As research into potential treatment methods for FXS grows, the lack of parental voice in 
the understanding of this genetic disorder’s treatment, intervention, and proposed outcome 
measures persists, resulting in a gap in current knowledge. The gap highlights the need to utilize 
parental perspectives through interviews as a tool to contribute to and expand upon current 
standardized outcome measures. Outcomes measures used currently to assess FXS are limited in 
scope and context, and lack the voices of families of children with FXS. Moreover, current 
standardized measures lack sensitivity to reflect changes over time and improvements in the 
context of daily living.  
Significance and Purpose of Study 
         The research aimed to provide a new lens into the perspectives of families and their 
experiences. Semi-structured, open-ended questions were used during the interviews with 
families participating in the clinical trial. The interview data was used to gauge whether there 
were experiential differences in activity level, communication, behavior, and sensory processing 
between the sertraline treatment group and placebo group. To a larger degree, the results of this 
study may demonstrate the significance of qualitative information from interviews to support 
clinical trials and will contribute to the growing need for re-evaluation of outcome measures used 
in future clinical studies. The purpose of this study was to examine family perspectives and how 
interviews can be used to understand family expressions and contexts of their child’s reported 
improvements over the course of the clinical trial. This qualitative data may be a more sensitive 
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measure in contrast to standardized measurements, which capture limited change over time 
within IDD populations.  
Research Question 
The research question that guided this study was: Can qualitative interview methods 
serve as an outcome measure capturing changes in occupational performance between treatment 
and placebo groups? 
Theoretical Framework 
         The theoretical frameworks that guided this study were Vygotsky’s sociocultural theory 
and the Person-Environment-Occupation (PEO) model (Law et al., 1996). These frameworks are 
related to this research study as they addressed the social, cultural, and environmental factors that 
both children with FXS and their families encountered on a daily basis (Hessl et al., 2001). 
Children with FXS have a genetic condition that manifests in a phenotypic expression of 
intellectual and functional disabilities (Wang, Berry-Kravis, & Hagerman, 2010). However, 
biology is not the sole determining factor of one’s functioning, therefore it is vital to also 
consider social and cultural factors in the growth and development of children with FXS. 
         Vygotsky’s sociocultural theory suggests that children’s cognition improves through 
social and cultural interaction (McLeod, 2016). This theory relates to the research as it 
incorporates family perspectives as a way to better understand FXS and potential treatment 
options. Each family’s social and cultural background influences the child’s development and 
experience of the world. According to McLeod (2016), “individual development cannot be 
understood without reference to the social and cultural context within which it is embedded.” 
The sociocultural theory guided this research study by showing how differing social and cultural 
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views affect both children with FXS and their families, and how those views can be useful in 
helping to understand FXS in a larger population. 
         Additionally, Vygotsky (1978) emphasized that learning and development are dynamic 
systems that go hand-in-hand. While the child is developing biologically, they are also learning 
from external sources like social interaction and their cultural environment. This theory relates to 
families of children with FXS as certain social and cultural interactions, such as occupational 
therapy, behavioral therapy, and special education, are likely impactful factors in the child with 
FXS’s learning and development. While these children will certainly have biological 
development and learning associated with FXS as a genetic diagnosis, it is critical to include the 
sociocultural theory as it brings an external component into the picture.  
         Just as the sociocultural framework creates an important grounding for the research in the 
dynamic interactions of biology and the environment, the PEO model also influences this study. 
The PEO model aims at optimizing the interaction and identifying the best fit between the 
person, environment, and occupation. This model guides occupational therapy intervention by 
providing a specific understanding for how the environment can have an effect on the person, 
and how they participate in their desired occupations. The PEO model also relates to families of 
children with FXS, as some environmental factors can have a great effect on how both the child 
with FXS and their families are able to participate in daily life. According to Law et al. (1996), 
the person develops dynamically and is always interacting with their environment. Through this 
model, occupational therapy intervention is targeted towards finding the best fit for the person in 
a specific environment. This relates to families of children with FXS, as it is important to 
understand that the physical, social, and cultural environment can all have a positive or negative 
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effect on how children with FXS and their families participate in daily occupations. By 
identifying ways to adjust the environment for children with FXS and their families, their ability 
to participate in their desired occupations will be further enhanced. 
Methodology 
Design 
This was a qualitative research study that employed interview methods. Semi-structured 
interviews were conducted at baseline and again at post-testing as part of the UC Davis MIND 
Institute randomized controlled trial of sertraline study, and audio-recorded (Hess et al., 2016). 
This research utilized data from 12 post-interviews (6 placebo and 6 treatment) conducted upon 
completion of the 6-month randomized controlled trial (see Figure 1).  At the time of the post-
interviews, families were still blind to their group assignment in the randomized controlled trial.  
Additionally, for this analysis, researchers were blind to the group assignment (6 placebo and 6 
treatment). The researchers then transcribed interview recordings verbatim using ExpressScribe. 
 




Figure 1.  Flow chart of UC Davis MIND Institute sertraline and FXS randomized clinical trial. Researchers 
conducted baseline interviews and assessments and then randomly grouped participants into either the treatment or 
placebo group.  After the 6-month clinical trial, a post interview and assessment was conducted. This research 
focused on the post-interviews. 
 
Population 
         The target population for this study was the parents or caregivers of children ages two to 
six years with FXS enrolled in the UC Davis MIND Institute’s randomized clinical trial of 
sertraline (Hess et al., 2016). A snowball recruiting procedure was used to gather the participants 
for the completed clinical trial at the UC Davis MIND Institute.  
Ethical Considerations  
Due to the sensitive nature of the interview data, private information was protected by 
assigning anonymous identification numbers to each participant and omitting names of children 
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and parents during the transcription process. Interview data was stored in a secure, locked 
location that was only accessible to researchers on site. The research team and assistants signed 
confidentiality statements (see Appendix A for interview protocol). Once data was anonymized, 
it was imported into Dedoose (www.dedoose.com), a secure, web-based mixed methods software 
application, for analysis. To further protect participants, data was made accessible to research 
members only via password protection.  
Data Collection 
The interviews were completed either at the UC Davis MIND Institute or via phone with 
an occupational therapist. Interviews were 45-60 minutes in length and were conducted in a 
conversation format and audio recorded on an iPad. The interview data base was obtained via 
written permission from the principal investigator of the UC Davis MIND Institute FXS and 
sertraline study. The Dominican University research team and assistants transcribed interviews 
verbatim using ExpressScribe transcription software. Transcriptions were then uploaded and 
stored in Dedoose. The Dominican University principal investigator assigned 12 out of 30 post 
clinical trial audio files to the researchers to code and analyze (6 placebo group and 6 sertraline 
group, all male subjects). Researchers were blind to group assignments of 12 audio files until the 
final stage of the data analysis process.   
Data Analysis  
The goal of the data analysis was to discover groupings, themes, or patterns from 
interview information including improvements in daily life and occupations. The constant 
comparison method (Corbin & Strauss, 1994) drove the data analysis, and the research team 
developed codes based on emergent themes via consensus and inductive analysis. Through 
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inductive analysis, themes, patterns, and categories “emerged out of the data rather than being 
imposed on them prior to data collection and analysis” (Dye, Schatz, Rosenberg, & Coleman, 
2000, p. 4). Analysis and interpretation of the data were guided by the chosen theoretical 
frameworks to provide an in-depth, sociocultural and occupation-centered context.  
Researchers began the initial categorizing and labeling of transcript excerpts. 
Observations from the interviews were compared and bits of data were grouped based upon 
similarities (Dye, Schatz, Rosenberg, & Coleman, 2000). Through this, researchers assigned 
meaning to the data by linking the interviewee’s responses to recurring concepts and categories. 
Categories were reviewed and refined following the initial category generation. This refining 
process clarified the initial categories, which were broad in scope to begin with, but became 
more precise through the process (Dye, Schatz, Rosenberg, & Coleman, 2000). Researchers then 
created codes and operationalized definitions for these categories (see Table 1). These definitions 
ensured codes were consistently applied. Each researcher independently coded three transcripts 
and used content analysis to compare primary patterns in the data and incidents. Then the 
researchers independently reviewed all coded transcription excerpts across all 19 thematically-
based codes. Themes were operationalized with further clarified code definitions (as necessary) 
and re-categorized according to patterns discovered in the data. Through consensus coding, 
100% agreement was reached by all four researchers across the 345 coded excerpts during 
analysis. 








The interviews were analyzed to determine whether or not there were differences in the 
aforementioned codes between the sertraline treatment and placebo groups. Percentage of codes 
that were applied to the sertraline treatment group and placebo group are represented in Figure 2.  
Codes are represented in italics and exemplar quotes are noted as stated by the families. Any 
names noted are pseudonyms. 
Anxiety  
Our data showed that the application of code Anxiety Not Improved were found more 
often (79%) in the placebo group than the sertraline treatment group (21%). Application of 
Anxiety Improved was more even, with 5/9 (56%) applied in the sertraline treatment group and 
4/9 (44%) in the placebo group. Parents’ descriptions of their child’s improvements in anxiety 
included an increase in coping with things or situations that caused anxiety. For example, a 
parent shared, “…because he knows oh I can climb this, I’ve done that.” Meanwhile, other 
parents noted that their child’s anxiety did not show improvement. A parent of one child 
remarked:  
He grabs you into a death hug. And it took a while to finally get him away from 
you a little bit so he can actually feel the water. That seems like a change for me. 
Like he's more clinging in the water. 
Proactive coping strategies for anxiety were noted among the children.  Another parent 
shared, “it stressed him out, taking his blanket and sucking on it. [It is] the only thing to calm 
him down.” 




Approximately 90% of Behavior Improved (Less) were coded in the sertraline treatment 
group (19/21) comparing with the placebo group (2/9). Parents’ descriptions of their child’s 
behavioral improvements in this category included a decrease in maladaptive behaviors such as 
less fussing, crying, frustration, and tantrums and an increase in desired behaviors such attention, 
independence, and purposeful actions. One parent stated, “His behavior is definitely getting 
better. The screaming has significantly decreased.” Another parent stated “he just isn’t as upset 
as much as he used to be.” Parents also noted that their child’s behavior did not improve. A 
parent stated, “He melts down sometimes but he just never stops.”    
 Approximately 89% of Behavior Improved (More) marked by an increase in attention, 
independence and purpose were observed in the sertraline treatment group (9/10). Out of 27 
codes applied for Behavior Not Improved marked by either no change or increase in meltdowns, 
tantrums, and rigidity, approximately 70% (19/27) were found in the placebo group. Thirty 
percent of the codes applied for Behavior Not Improved belonged to the sertraline treatment 
group. The code Behavior Proactive Strategies was applied in seventeen excerpts. Of these 
seventeen, thirteen (76%) were applied to the placebo group and four (24%) were applied to the 
sertraline treatment group.  
Communication  
Of the twelve coded transcripts, communication related codes were identified most 
frequently (68/345) in our study. Communication related codes include Communication 
Improved Expressive, Communication Improved Receptive, and Communication Not 
Improved. The application of Communication Improved Expressive appeared 38 times 
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(56%) in the sertraline treatment group and 30 times (44%) in the placebo group. 
Improvements in receptive communication emerged 12 times out of 17 in the sertraline 
treatment group, which comprises (70%) of the category. The code, Communication Not 
Improved was applied eight times and was distributed equally between sertraline treatment 
and placebo group (four in each group). The application of code Communication 
Proactive Strategies was found eight times in our data. A majority (6/8) of code 
Communication Proactive Strategies was applied in the placebo group. Parents’ 
descriptions of their child’s improvements in communication included changes in 
expressive and receptive language. For example, a transition was noted by a parent who 
stated, “He grabbed his bag because he thinks there's cheerios in there and that's 
something new he doesn’t do it that often.” When the researcher asked if this 
communication emerged in the last six months, the parent replied, “I think so, as I 
remembered it as it pronounced.” Another parent expressed:  
He's doing so much better. And then he...so I feel like he has done...it’s fun it’s a lot 
of fun to see the different words he will end up with and he will pop up with 
different words that we didn’t know that he would know he will just say things like 
“awesome.” Like you’re awesome, you’re awesome, and he will say “awesome.” 
However, this study’s data also revealed communication that was not improved for some 
subjects. For example, one parent stated, “…but if not he gets upset he wants to get up he'll 
absolutely bang his head against the board being bruised.” Another parent shared, “he doesn’t 
have control and he doesn’t know how to express it.” Our data shows that some children and 
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their families employed proactive strategies for communication as alternatives to verbal or 
nonverbal communication.  For example, one parent explained: 
So we use the sounding board app so he takes me to the one app, tells me what he 
wants, then gives this back to me… if he can’t say something he likes he knows 
he can go to the sounding board and then say it. Point to whatever it is that he 
wants and then you know [...] what he needs. 
Function 
Difference in functional improvement did not differ between the two groups. The same 
number of 19 applications of Functional Improvement was applied to both sertraline treatment 
(50%) and placebo group (50%). Functional Not Improved themes was found frequently in the 
placebo group, (16/18 times or 89%), comparing with 2/18 (11%) in the sertraline treatment 
group.  Parents’ descriptions of their child’s functional improvements included activities of daily 
living and safety.  One parent pointed out, “…now he's sitting, and he can attend to tasks.  Like 
today, he put together 3 puzzles.” Another parent remarked his child is “…willing to try to get up 
and get on and actually play.” 
Community & Social 
Differences in community and social improvements were not found between the 
sertraline treatment and placebo groups. Out of the 18 applications of code Community/ Social 
Improved, eight were found in the sertraline treatment group and 10 were found in the placebo 
group. However, more non-improvements were coded in the placebo group, with seven out of 
eight applications (88%). Parents’ descriptions of their child’s improvements in the community 
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or in social environments included instances at the grocery store, parties, and family events. Such 
improvements are expressed by one parent in that: 
He's been happier lately. I don't care what everyone says. He just has a lot happier 
moments and days. The report from school, all the teachers love him because he 
runs down the hall and he hugs them and the minute you sat down next to (him), 
you can get him to engage you right away. I think that's some difference with him. 
In contrast, another parent noted that his child did not improve in community/social 
settings. He stated:  
He still has a hard time when we walk into large crowds or groups or when 
people are coming at him. For example, we had a birthday party for his mom and 
we walked into the room and people getting him in the room first was like a feat 
because he knew that there was a lot of people.  So he was like dragging his feet. 
He wanted to go the other direction. I picked him up and what he does is he will 
let us and pull our hair, grab our faces, and just pull. 
Sensory  
Sensory related code was found least frequently (18/345) across the transcripts. The code 
Sensory Improved (Less) was applied three times and came from the sertraline group. The 
application of Sensory Improved (More) was applied to four excerpts. Seventy-five percent of the 
Sensory Improved (More) codes were applied to the placebo group and 25% were applied to the 
sertraline treatment group. The application of Sensory Not Improved was applied to 11 excerpts. 
Seven out of 11 of these codes were applied to the placebo group and 4 out of eleven codes were 
applied to the sertraline group. Of the eighteen applications of the code Sensory Proactive 
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Strategies, eleven (61%) were applied to the placebo group and 7 (39%) were applied to the 
sertraline group.  
Parents’ descriptions of their child’s improvements in sensory included an increase of 
desired responses to sensation such as more tolerance or more exploration of sensations or a 
decrease in maladaptive responses to sensation such as a decrease in self-stimulation, sensory-
seeking, defensiveness, and avoidance. One parent stated, “I have been a lot better at, (wife) has 
too, about swinging him upside down and rubbing and massage him.” 
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 Figure 2. Percentage of codes applied to the sertraline treatment and placebo groups.  




The research question that guided this study was: Can qualitative interview methods 
serve as an outcome measure capturing changes in occupational performance between treatment 
and placebo groups? Findings suggest that qualitative interview methods have good potential to 
serve as a supplemental outcome measure in a clinical trial. Interview methods provide 
opportunities for parents of children with FXS to describe changes in their child’s behavior, 
anxiety, communication, function, sensory processing, and social interaction within a holistic 
context which are less detectable by standardized norm-referenced assessments. Moreover, 
participation in a clinical trial has had an effect on both the child with FXS and their families’ 
ability to participate in their desired occupations.  
The ability of parents to detect changes in their child’s expressive communication further 
prompts the necessity of interview methods as an outcome measure. For example, parents 
described that their children used gestures, such as pointing or hand-leading, which may be 
communication strategies that are less detectable in standardized tests. Furthermore, parents 
reported improvements in Behavior Less through decreased maladaptive behaviors in several 
daily contexts. This indicates that interviews can serve as an outcome measure as they capture a 
more detailed description of changes in day to day life, where standardized assessments are 
likely to focus on only one point in time.  
Inconsistent results were reported within sensory improvements between Sensory 
Improved (More) and Sensory Improved (Less). All Sensory Improved (Less) improvements were 
found in the sertraline treatment group and the majority of Sensory Improved (More) 
improvements were found in the placebo group. Each parent, regardless of group assignment, 
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was given sensory proactive strategies by the occupational therapist to improve their child’s 
sensory processing. While the results were inconsistent, parents were still able to report the types 
of sensory strategies that were effective and strategies that were not, thus showing the 
importance of interview methods during a clinical trial as standardized assessments may not 
capture the types of strategies used and their effectiveness on sensory processing.  
Improvements in community and social participation reflect an increase in the child’s 
participation in events such as going to the grocery store, park, family events, parties, and social 
interactions with peers, siblings, and adults. Hess et al.’s (2016) study showed that the sertraline 
treatment group had “nominal significant improvements in the social participation subscale raw 
score from the SPM-P” (p.7) and showed that families indicated positive changes in social 
aspects of daily routines. However, this study’s results indicated that the placebo group reported 
more improvements in community and social participation than the sertraline treatment group. 
As a whole, the participants’ ability to detect improvements in the community and with social 
interactions supports results from Tomlin and Swinth’s (2015) study which stated that 
incorporating semi-structured caregiver interviews can provide an occupation-centered lens to 
research studies examining living with FXS and its impact on family life.  
Analysis of the semi-structured interviews with the codes defined in Table 1 revealed 
differences between the sertraline treatment and placebo groups in many areas. These results 
support the potential for interview methods to serve as outcome measures to capture changes in 
occupational performance between sertraline treatment and placebo groups in a clinical trial. 
These results are in line with Berry-Kravis et al.’s (2013) discussion of outcome measures in 
FXS noting standardized outcome measures lack sensitivity for IDD populations, prompting a 
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need for further outcome measures that are sensitive enough to small changes. This study was 
able to provide a qualitative measure that was effective in detecting changes in observable 
behaviors in children with FXS (Merriam, 2009). 
The sociocultural theory and PEO model guided this research study. The sociocultural 
theory displays how differing social and cultural views affect both children with FXS and their 
families, and how those views can be useful in helping to understand FXS in a larger population 
(Vygotsky, 1978). The PEO model displays how environmental factors can have a great effect on 
how both the child with FXS and their families are able to participate in daily life (Law et al., 
1996). These theoretical frameworks guided the data analysis as they helped researchers to focus 
on certain social and cultural interactions within the child’s environment and how those factors 
impacted the family’s daily life.  
Data themes provided an in-depth, sociocultural and occupation-centered understanding 
of family perspectives in realistic and contextual situations within the larger bioecological 
framework of the sertraline clinical trial (Hess et al., 2016). Parents perspectives can help 
achieve a good fit between person, environment, and occupations to optimize performance (Law 
et al., 1996). Some personalized strategies to address behavioral, sensory processing, and anxiety 
needs were mentioned in the interviews. Environmental modifications, such as decreasing 
sensory input, packing bags with books and toys, and PECS, were helpful in managing some 
sensory processing, communication, and behavioral issues. In this way changing the child’s 
environment allowed for optimal occupational performance (Law et al., 1996).  
As preliminary results from this study show, altering a part of the child’s biological 
process via medication has had an effect on the social and cultural interaction between children 
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with FXS, their families, and other individuals. For example, some children were able to 
participate in social settings, such as family events and even grocery shopping, which was less 
likely before participating in the clinical trial. Additionally, Vygotsky (1978) emphasized the 
dynamic systems in learning. As interactions with parents are crucial to the child’s development, 
the interview data can shed light on their communication methods, behavioral management 
approaches, sensory strategies, and adaptations in functional performance. Occupational 
therapists can take these perspectives into consideration when choosing a model to create 
treatment plans. 
Implications for Occupational Therapy Practice 
This study is important to the FXS community and to occupational therapy practice as 
functional participation in occupations is a crucial part to successful child development. Children 
with FXS have deficits in behavior, anxiety, sensory processing, and social participation that 
impact their families. Therefore, it is important for occupational therapists, as well as other 
disciplines, to guide treatment approaches for FXS with empirical research to address these 
issues. Using a top-down approach beginning with meaningful occupations to evaluate and treat 
the child, multidisciplinary teams should design evidence-based intervention strategies to 
promote greater occupational performance in children with FXS (Merriam, 2009; Portney & 
Watkins, 2015). The use of family perspectives will enrich therapists’ understanding of the lived 
experience of FXS, which can further help guide occupation-based, client-centered intervention 
and give meaningful outcomes for children and their families. 
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Limitations and Future Directions 
This research has limitations that should be considered. Firstly, researchers did not create 
“mother” codes such as behavior improved or communication improved for excerpts that did not 
specify which area the improvement occurred (more or less, receptive or expressive); creating a 
general code would have prevented researchers from having to assign two codes, or no code at 
all, to the excerpts. Another limitation is that member checks were not possible as the original 
sertraline study had been completed prior to this analysis.  Finally, this study only examined the 
post- interview.  
Future studies may examine the remaining questions in the interview protocol to gather 
additional information about the parents’ thoughts of the clinical trial and their hopes of the 
research in order to add a holistic, family-centered approach. Our data reported frequency of 
code applications in percentages. Future research with additional data may be able to compare 
groups with more robust statistical analyses. Additionally, future research may consider a 
comparison analysis between the baseline interview and the post-testing interview of each 
subject for a case-based thorough analysis. This will help therapists gain insight into how parents 
saw their children before the clinical trial and what aspects of their child’s behaviors and 
disability concern them most.  
Conclusion 
FXS is the most common form of inherited IDD and the most common single gene cause 
of ASD. The behavioral phenotype includes cognitive impairments, SIB, anxiety, global 
language delays, sensory processing deficits, and decreased social participation. These behaviors 
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not only affect the children with FXS, but their families as well. To date, research literature has 
focused primarily on quantitative methods and the medical model. While standardized and norm-
referenced assessments and parent checklists are widely used as outcome measures, their ability 
to detect contextually-based change is limited. The addition of supplemental, semi-structured 
interviews revealed differences between sertraline treatment and placebo groups in many coded 
areas in this sample. 
This study examined family interview data collected from a FXS clinical trial at the UC 
Davis MIND Institute (Hess et al., 2016) to measure the potential for family reports to serve as a 
qualitative outcome measure. The results support the potential for interview methods to serve as 
an outcome measure when used in conjunction with standardized and norm-referenced 
assessments and parent checklists in a clinical trial. Similarly, these results indicated that 
interview methods show potential to identify contextually-based differences between the 
treatment and placebo groups in a clinical trial. The addition of qualitative interview methods 
can provide family voice and personal stories and an occupation-centered lens. Our research also 
revealed the feelings of altruism that families experienced through participating in the clinical 
trial at the UC MIND Institute (Hess et al., 2016). Families in both sertraline treatment and 
placebo groups reported that regardless of the outcome of the clinical trial, they hoped that 
knowledge gained from this study may inform scientific research and its consumers, and 
ultimately benefit future generations of children with FXS and their families.  
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Interview Protocol – Sertraline 
Annual Review (June, 2013) 
 
The interviews will be conducted either at the MIND Institute or via phone with a MIND FXS research 
clinician.  Interviews will be conducted in a conversation format, audio recorded and transcribed for 
qualitative coding of the interview data.  All personal information will remain confidential and pseudonyms 
will be used.  The following questions will structure the overall interviews, yet, because the interview 
process is based on emergent responses, probes and follow up questions may be added as appropriate to 
clarify or expand upon responses provided by the interviewees.  The interviews should average 30-45 
minutes in length. 
Baseline 
 
The purpose of the interview is to gain insight 
into family perspectives from their point of 
view, in their own words, regarding issues 
surrounding participating in a clinical trial 
with a 2-6 year old child diagnosed with FXS.  
Please share stories, anecdotes and “for 
examples” as they come to mind as these rich 
descriptions are very meaningful and important 
to our research. 
 
1. Tell me about (child’s name).  I realize 
we are all here at the MIND for specific clinical / 
research reasons, but I want to back up and talk 
about your child as a little person who has 
strengths, gifts and talents.  I especially want to 
hear stories about the kinds of things you enjoy 
about (child’s name). 
 
2. Tell me about your child’s activity level / 
behavior? How do you feel anxiety may or may 
not play a part in behavior?  Tell me a story 
about how this may impact you as a family? 
 
3. What do you notice about your child’s 
reactions to sensory input? (moving through 
space, sound, touch, smelling things, eating). 
Tell me a story about how this may impact you 
as a family? 
 
6 month appointment – prior to family “unblinding” 
 
During our first interview we were able to discuss your 
child’s strengths and patterns including behavior, 
sensory, anxiety and communication and the impact 
on your family. As a follow up to that conversation, 
today I would like us to discuss any changes you have 
seen since beginning the study in these areas and the 
impact to your family.  Again, please share stories, 
anecdotes and “for examples” as they come to mind as 
these rich descriptions are very meaningful and 
important to our research. 
 
1. Let’s start with activity level and behavior.  
What changes if any have you noticed and how has that 
impacted you as a family. 
 
2. Have you noticed any changes related to 
anxiety? How has that impacted you as a family? 
 
3. Have you noticed any changes related to sensory 
processing?  How has that impacted you as a family? 
 
4. Have you noticed any changes related to 
communication? How has that impacted you as a 
family? 
 
5. Do you think you were given the placebo or the 
medication? What were you observing / feeling that has 
led you to wonder whether you had the medication or 
not? 
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4. Tell me about your child’s abilities in 
communicating with you? Other family 
members? Other children? Tell me a story about 
how this may impact you as a family?  
 
***5. What interventions are you 
participating in currently including school 
and/or therapies (such as OT / speech)? Is there 
anything you would like to see changed about 
your child’s intervention situation or the way he 
or she is during intervention / services? 
 
6. What has led you to participate in 
research that includes a trial of medication?   
 
7. Tell me your feelings about the 
possibility that your child may get the real 
medication? Tell me your feelings about the 
possibility that your child may get the placebo?  
 
8. What are your expectations and/or hopes 
for this research study for your family in 
particular? What does participating in this type 
of research mean to you and your family?   
 
9. Is there anything you would like to share 
in terms of your family’s involvement in the 
research study regarding what you have learned 
thus far and what your hopes are for overall or 





6. Is there anything you would like to share in 
terms of your family’s involvement in the research study 
regarding what you have learned thus far and what your 
hopes are for overall or big picture learning that can 
come out of the research? 
 
 
